Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SS4P
|
|||
| Former ID |
DAP000249
|
|||
| Drug Name |
Pirbuterol
|
|||
| Synonyms |
Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Approved | [1], [2] | |
| Therapeutic Class |
Bronchodilator Agents
|
|||
| Company |
3M Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H20N2O3
|
|||
| Canonical SMILES |
CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O
|
|||
| InChI |
1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3
|
|||
| InChIKey |
VQDBNKDJNJQRDG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 38677-81-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10009, 5518522, 8152979, 10320223, 11407589, 15196418, 29223926, 46506379, 49967589, 57322484, 80738546, 85220239, 96025073, 103749740, 104307595, 125679197, 129511004, 134221951, 134337563, 135001188, 137054085, 137619489, 160964608, 163078219, 172873513, 178103846, 179150409, 223440681, 224856379, 226396743, 241067986
|
|||
| ChEBI ID |
CHEBI:8245
|
|||
| ADReCS Drug ID | BADD_D01781 ; BADD_D01782 | |||
| SuperDrug ATC ID |
R03AC08; R03CC07
|
|||
| SuperDrug CAS ID |
cas=038677815
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-2 (ADRB2) | Target Info | Agonist | [3], [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Salivary secretion | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta2 adrenergic receptor signaling pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Vitamin D Receptor Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7272). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32. | |||
| REF 4 | A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 p... Oncogene. 2007 May 31;26(26):3777-88. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.